S-equol and PD-1 Inhibitors Synergy Melanoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for melanoma and triple-negative breast cancer show limited efficacy, with PD-1/PD-L1 axis therapies only effective for a subset of patients, highlighting the need for alternative treatments that enhance immune response against cancer cells.
Innovation Solution
The use of S-equol, an ERβ agonist, in combination with immunotherapy, specifically with PD-1 inhibitors, to boost antitumor immune responses by modulating CD8+ T cell activity and enhancing immune cell infiltration and function within tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1/PD-L1 axis immunotherapy is used to treat melanoma, then antitumor immune response is activated, but therapeutic efficacy is limited and only effective for a subset of patients
Solution Approach 1:
The patent combines PD-1 inhibitor immunotherapy with S-equol (an ERβ agonist) to create a synergistic treatment approach. This combination merges the immune activation mechanism of PD-1 blockade with the hormonal modulation effects of S-equol, resulting in enhanced antitumor immunity and improved therapeutic efficacy compared to monotherapy alone.
Solution Approach 2:
S-equol acts as an intermediary substance that modulates the immune response generated by PD-1 inhibitors. By binding to ERβ receptors in tumor cells and immune cells, S-equol enhances the effectiveness of PD-1 blockade, serving as a mediator that amplifies the overall therapeutic effect.
2Reliability
If monotherapy with PD-1 inhibitor is used, then treatment simplicity is maintained, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent merges PD-1 inhibitor therapy with S-equol administration to overcome the limitations of monotherapy. This combination approach, while increasing treatment complexity, significantly improves therapeutic efficacy by addressing multiple mechanisms of cancer progression simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
S-equol in combination with PD-1 inhibitors significantly reduces tumor volume and weight, demonstrating improved therapeutic efficacy compared to monotherapy, suggesting a synergistic effect in treating melanoma by enhancing antitumor immunity.
Implementation Method 1
S-equol, an ERβ agonist, in combination with immunotherapy, specifically with PD-1 inhibitors, to boost antitumor immune responses by modulating CD8+ T cell activity
Implementation Method 2
boost antitumor immune responses by modulating CD8+ T cell activity and enhancing immune cell infiltration and function within tumors
Implementation Method 3
blocking the immune-suppressive immune checkpoint molecules CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 or CD152), PD-1 (programmed cell death protein 1), and PD-L1 (programmed death ligand 1)
Data Source
AI summary
The present invention provides methods and compositions for treating or preventing melanoma with S-equol. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.